Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Foamix Pharmaceuticals Ltd. (FOMX)
|
Add to portfolio |
|
|
|
| Price: |
$3.35
| | Metrics |
| OS: |
61.6
|
M
| |
542
|
% ROE
|
| Market cap: |
$206
|
M
| |
-623
|
% ROIC
|
|
Net cash:
|
$39.4
|
M
| |
$0.64
|
per share
|
|
EV:
|
$167
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($95.5)
|
M
| |
|
|
|
EBIT
|
($95.9)
|
M
| |
|
|
| EPS |
$1.70
| |
2.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.4 | 3.6 | 3.7 | 5.5 | 0.8 | 5.4 |
| Revenue growth | -87.7% | -2.0% | -33.6% | 551.0% | -84.3% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.5 |
| Gross profit | 0.4 | 3.6 | 3.7 | 5.5 | 0.8 | 4.9 |
| Gross margin | 100.0% | 100.0% | 99.6% | 98.9% | 91.8% | 90.3% |
| Selling, general and administrative | 45.1 | 14.0 | 11.5 | 9.2 | 7.0 | 3.0 |
| Research and development | 51.2 | 64.5 | 57.8 | 25.9 | 10.7 | 3.6 |
| EBIT | -95.9 | -74.9 | -65.6 | -29.7 | -16.9 | 1.6 |
| EBIT margin | -21641.8% | -2083.2% | -1788.3% | -536.5% | -1994.1% | 30.2% |
| Pre-tax income | 95.4 | 74.0 | 64.6 | 28.9 | 16.5 | 11.5 |
| Income taxes | 0.2 | -0.2 | -1.2 | -0.4 | 0.0 | 0.0 |
| Tax rate | 0.2% | | | | | |
| Net income | 95.2 | 74.2 | 65.7 | 29.3 | 16.5 | 11.5 |
| Net margin | 21484.9% | 2062.9% | 1791.1% | 530.8% | 1945.5% | 212.1% |
| |
| Diluted EPS | $1.66 | $1.70 | $1.76 | $0.91 | $0.59 | $0.79 |
| Shares outstanding (diluted) | 57.3 | 43.7 | 37.4 | 32.3 | 28.2 | 14.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|